Conference papers

A phase II randomised, double-blind, placebo-controlled, proof of concept study of oral seletalisib in patients with primary Sjögren’s syndrome (PSS).

Maria Juárez ¹ Nieves Diaz ¹ Geoffrey I Johnston ¹ Saba Nayar ² Andrew Payne ¹ Eric Helmer ¹ Dionne Cain ¹ Paulette Williams ³ Wan Fai Ng ⁴ Benjamin Fisher ² Jacques-Eric Gottenberg ⁵ Giuliana Guggino ⁶ Xavier Mariette ⁷ Marika Kvarnström ⁸ Valérie Devauchelle-Pensec ^{9, 10} Jose Rosas ¹¹ Juan Sanchez-Burson ¹² Roberto Giacomelli ¹³ Francesca Barone ² Simon J Bowman ¹⁴

1 UCB Pharma [Slough]

2 University of Birmingham [Birmingham]

3 UCB Pharma Raleigh

4 University of Newcastle, Newcastle upon Tyne, UK

5 University Hospital of Strasbourg

6 University of Palermo, Italy

7 Service de rhumatologie

8 Department of Medicine - Unit of Experimental Rheumatology, Stockhom

9 CHU - BREST - Rhumato - CHRU Brest - Service de Rhumatologie

10 LBAI - Lymphocytes B, Autoimmunité et Immunothérapies

11 Hospital Marina Baixa, Villajoyosa

12 Infantaluisa Hospital, Sevilla

13 UNIVAQ - University of L'Aquila [Italy]

14 University Hospital Birmingham

Document type :

Conference papers

Domain :

Life Sciences [q-bio] / Immunology

Complete list of metadata

https://hal.univ-brest.fr/hal-02150798
Contributor : Geneviève Michel Connect in order to contact the contributor
Submitted on : Friday, June 7, 2019 - 2:34:54 PM
Last modification on : Saturday, June 25, 2022 - 9:12:42 PM